Kevin Krause

Mr. Krause has more than 20 years of experience in the biopharmaceutical industry, spanning R&D, Corporate Business Development, Commercial Strategy, and Operations within Infectious Diseases and Respiratory Medicine. He has been a key contributor and team-leader for three US INDs, five New Drug Applications (NDAs), five Marketing Authorization Applications (MAAs), four US FDA Anti-infective Drug Advisory Committee meetings, and numerous product launches in both the US and Europe.

Prior to joining AN2 Therapeutics, Mr. Krause was the Sr. Director and Head of Microbiology and later the Sr. Director of Corporate Development at Achaogen. Previously, Mr. Krause was a member of the Clinical Microbiology team at Cerexa, Inc. (A subsidiary of Forest Laboratories/Actavis/Allergan now Abbvie) and played a key role on the Scientific Assessment teams for all antibacterial and antiviral in-licensing opportunities. For the 11 years prior, Mr. Krause served in various Research and Clinical Microbiology roles at Theravance. Mr. Krause has been instrumental in the clinical development and approval of ZEMDRI® (plazomicin), AVYCAZ® (ceftazidime-avibactam) and VIBATIV® (telavancin), contributed to the regulatory defense, and launch of Teflaro® (ceftaroline fosamil) and represented the Microbiology function on the global product teams for Colobreathe® (inhaled colistin) and Quinsair® (inhaled levofloxacin). He has also provided functional and team leadership to numerous research programs from early discovery through Phase 1. He is an author of >50 peer-reviewed publications, more than 150 meeting abstracts, one book chapter, and one patent. He has been an invited speaker at a number of industry related forums and conferences and FDA and EMA guidance document development workshops. Mr. Krause earned an MBA from the University of California, Berkeley Haas School of Business, and a BS in Molecular Biology from San Francisco State University.